Laura Shawver - 24 Jun 2026 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
26 Jun 2026, 16:15:08 UTC
Prior SEC filing
27 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kathleen Scott, Attorney-in-Fact

Key filing fact

Laura Shawver filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 26 Jun 2026.

Key facts

  • This page summarizes Laura Shawver's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 26 Jun 2026, 16:15.

Change

  • Previous filing in this sequence was filed on 27 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001551891 Primary reporting owner

Shawver Laura

Relationship
Director
Address
C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Signature date
26 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRY transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+30,000
Change %
Price
$0.000000*
Shares after
30,000
Date
24 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$10.54
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .